CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ:LIFE) today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life science industry’s widest array of products to support cell therapy applications, including regenerative medicine. Specifically designed to help cell therapy practitioners accelerate the transition from research to clinical applications, the product portfolio will include a broad and deep offering of Invitrogen devices and reagents.
